The latest announcement is out from Werewolf Therapeutics (HOWL).
Werewolf Therapeutics, Inc. revealed encouraging initial results from their ongoing Phase 1/1b clinical trial of WTX-124, showing potential in treating advanced solid tumors post-checkpoint inhibitor therapy. The data, presented at the ASCO Annual Meeting, indicated that WTX-124, both alone and combined with pembrolizumab, elicited tumor regression and was generally well-tolerated. The company has established a recommended dose for further study and is planning to discuss accelerated approval pathways for WTX-124, bolstered by additional positive observations in melanoma patients.
See more data about HOWL stock on TipRanks’ Stock Analysis page.
